Allmed Medical(SZ:002950) Dong Jian Yan Bao·2025-06-12 15:23Report Summary 1. Report Industry Investment Rating No information provided. 2. Core View of the Report - The company, as the leader in the overseas medical dressing market, has built a deep moat. It implements a dual - wheel drive strategy at home and abroad, aiming to increase its domestic market share in the future. The company also attaches great importance to shareholder returns [21][23]. 3. Summary According to the Directory 3.1. Research Basic Situation - The research object is Aomei Medical, belonging to the medical device industry. The reception time was on June 12, 2025, and the company's reception staff included the chairman and president Cui Jinhai, and the board secretary Zheng Xiaocheng [16]. 3.2. Detailed Research Institutions - The reception objects were investors who participated online in the "Improving Quality and Efficiency, Strengthening Confidence, Making Progress Steadily and Promoting Development" - 2025 Investor Collective Reception Day Activity for Listed Companies in Hubei Province and the 2024 Annual Performance Briefing [17]. 3.3. Research Institution Proportion No information provided. 3.4. Main Content Data - Stock Price and Market Recognition: The secondary - market price is affected by multiple factors. The fundamental way to safeguard the interests of listed - company shareholders is to operate the company well and achieve long - term shareholder value. The company has a deep moat as the overseas medical dressing market leader and is implementing a dual - wheel drive strategy [21][23]. - Sales Revenue Distribution: In 2024, the company's overseas operating income was 2.7565 billion yuan, a year - on - year increase of 23.43%, accounting for 82.87% of the operating income. The domestic income was 569.7916 million yuan, a year - on - year increase of 8.86%, accounting for 17.13% of the operating income. The company has been the number one in China's medical dressing export industry for 17 consecutive years since 2008 [22][23]. - Dividend Policy: The company meets the regulatory requirements for dividends. The cumulative cash dividends from 2018 - 2024 (including proposed dividends) are about 1.099 billion yuan, reaching 2.29 times the net amount of the company's raised funds. The reduction in cash dividends in the past two years is due to the company's strategic upgrade and future capital expenditure plans [24]. - New Development Goals: The company will focus on four types of products: surgical and wound care products to expand overseas market share; infection - prevention products to be promoted in both domestic and foreign markets; advanced dressing products with rich technical reserves and self - designed production lines; and health - care products in the family - care field, which are still in the initial stage [25][26].